PTCT

PTC Therapeutics, Inc.

66.09

USD

PTCT Earnings Reports

Positive Surprise Ratio

PTCT beat 14 of 41 last estimates.

34%

Next Report

Date of Next Report

Apr 23, 2026

Estimate for Q1 26 (Revenue/ EPS)

$229.69M

-$0.49

Implied change from Q4 25 (Revenue/ EPS)

+7.73%

-70.66%

Implied change from Q1 25 (Revenue/ EPS)

-80.47%

-104.89%

PTC Therapeutics, Inc. earnings per share and revenue

On Feb 19, 2026, PTCT reported earnings of -1.67 USD per share (EPS) for Q4 25, missing the estimate of 0.03 USD, resulting in a -4460.31% surprise. Revenue reached 213.20 million, compared to an expected 282.20 million, with a -24.45% difference. The market reacted with a +1.09% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 10 analysts forecast an EPS of -0.49 USD, with revenue projected to reach 229.69 million USD, implying an decrease of -70.66% EPS, and increase of 7.73% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

Acumen Pharmaceuticals, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.46

Actual

-$0.41

Surprise

+11.29%

Humacyte, Inc. Common Stock

Report Date

Mar 27, 2026 For Q4 25

Estimate

-$0.13

Actual

-$0.13

Surprise

+3.20%

Rani Therapeutics Holdings, Inc. Class A Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.07

Surprise

-2.94%

Spero Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.20

Actual

$0.53

Surprise

+359.80%

Alpha Cognition Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.30

Surprise

-8.93%

Cognition Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.02

Surprise

+76.47%

Entera Bio Ltd. Ordinary Shares

Report Date

Mar 27, 2026 For Q4 25

Estimate

-$0.09

Actual

-$0.07

Surprise

+23.75%

Quantum Biopharma Ltd. Class B Subordinate Voting Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

Actual

-$0.71

Surprise

CollPlant Biotechnologies Ltd Ordinary Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.67

Surprise

-245.72%

FAQ

What were PTC Therapeutics, Inc.'s earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, PTC Therapeutics, Inc. reported EPS of -$1.67, missing estimates by -4460.31%, and revenue of $213.20M, -24.45% below expectations.

How did the market react to PTC Therapeutics, Inc.'s Q4 2025 earnings?

The stock price moved up 1.09%, changed from $69.90 before the earnings release to $70.66 the day after.

When is PTC Therapeutics, Inc. expected to report next?

The next earning report is scheduled for Apr 23, 2026.

What are the forecasts for PTC Therapeutics, Inc.'s next earnings report?

Based on 10 analysts, PTC Therapeutics, Inc. is expected to report EPS of -$0.49 and revenue of $229.69M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.